Biased Ligands. Better Drugs.

Oliceridine pivotal Phase 3 hard-tissue results (APOLLO-1)

APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the ยต-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy

Eugene R. Viscusi MD, Franck Skobieranda MD, David G. Soergel MD, Emily Cook, David A. Burt PhD, Neil K. Singla MD

View Publication

Copyright © Trevena, Inc.